S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
NASDAQ:SNY

Sanofi (SNY) Stock Forecast, Price & News

$53.53
-0.16 (-0.30%)
(As of 08/11/2023 08:49 PM ET)
Compare
Today's Range
$52.91
▼
$53.53
50-Day Range
$50.52
▼
$54.95
52-Week Range
$36.91
▼
$57.82
Volume
1.66 million shs
Average Volume
1.68 million shs
Market Capitalization
$135.15 billion
P/E Ratio
18.33
Dividend Yield
2.58%
Price Target
$82.40
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Sanofi MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
53.9% Upside
$82.40 Price Target
Short Interest
Healthy
0.17% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
1.18mentions of Sanofi in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.30%
From $4.46 to $4.83 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.85 out of 5 stars

Medical Sector

38th out of 988 stocks

Pharmaceutical Preparations Industry

14th out of 460 stocks

See Top Rated MarketRank™ Stocks Here

SNY stock logo

About Sanofi (NASDAQ:SNY) Stock

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Price History

SNY Stock News Headlines

August 1, 2023 | marketbeat.com
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist (SNY)
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
July 27, 2023 | marketbeat.com
Exscientia is the Sniper of the AI Drug Discovery Industry (SNY)
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion
August 14, 2023 | Behind the Markets (Ad)
Here's something only a handful of people know
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
August 10, 2023 | finance.yahoo.com
Why Shares of MacroGenics Are Jumping Thursday
August 8, 2023 | stocknews.com
3 Pharma Stocks Investors Are Chasing for Value
August 8, 2023 | msn.com
Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy
August 8, 2023 | americanbankingnews.com
Sanofi (NASDAQ:SNY) Raised to "Strong-Buy" at StockNews.com
August 7, 2023 | americanbankingnews.com
Sanofi (NYSE:SNY) Upgraded to "Strong-Buy" at StockNews.com
August 14, 2023 | Chaikin Analytics (Ad)
Wall Street Insider Makes Prediction about Hot A.I. Stock
50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.
August 5, 2023 | americanbankingnews.com
Sanofi (NASDAQ:SNY) Rating Increased to Strong-Buy at StockNews.com
August 4, 2023 | americanbankingnews.com
Sanofi (NASDAQ:SNY) Upgraded by StockNews.com to Strong-Buy
July 30, 2023 | insidermonkey.com
Sanofi (NASDAQ:SNY) Q2 2023 Earnings Call Transcript
July 28, 2023 | finance.yahoo.com
Sanofi (SNY) Q2 2023 Earnings Call Transcript
July 28, 2023 | finance.yahoo.com
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
July 28, 2023 | finance.yahoo.com
Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down
July 28, 2023 | benzinga.com
Sanofi Reports Lower Q2 Earnings, But Lifts 2023 Outlook On New Drug Launches
July 28, 2023 | seekingalpha.com
Sanofi 2023 Q2 - Results - Earnings Call Presentation
July 28, 2023 | finance.yahoo.com
Press release: Online availability of Sanofi’s half-year financial report for 2023
July 28, 2023 | seekingalpha.com
Sanofi Non-GAAP EPS of €1.74, revenue of €9.96B; raises FY23 guidance
July 28, 2023 | seekingalpha.com
Sanofi to grow 'healthy aging' segment with Qunol acquisition
July 25, 2023 | ca.finance.yahoo.com
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
July 21, 2023 | finance.yahoo.com
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
July 20, 2023 | msn.com
Sanofi: Powering Up And Offering Investors A Lot Of Potentials
July 19, 2023 | seekingalpha.com
Sanofi expands collaboration with Scribe on CRISPR genome editing
July 17, 2023 | finance.yahoo.com
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 11, 2023 | finance.yahoo.com
This is Why Sanofi (SNY) is a Great Dividend Stock
June 27, 2023 | msn.com
Sanofi's Amlitelimab Hits Primary Goal In Mid-Stage Atopic Dermatitis Study
See More Headlines
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Company Calendar

Ex-Dividend for 6/23 Dividend
5/30/2023
Dividend Payable
6/23/2023
Last Earnings
7/28/2023
Today
8/13/2023
Next Earnings (Estimated)
10/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNY
CUSIP
N/A
CIK
1121404
Web
www.sanofi.com
Phone
(315) 377-4000
Fax
33-1-53-77-43-03
Employees
91,573
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$82.40
High Stock Price Forecast
$93.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+53.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.92
Trailing P/E Ratio
18.33
Forward P/E Ratio
12.00
P/E Growth
1.6
Net Income
$8.82 billion
Net Margins
16.07%
Pretax Margin
25.40%
Return on Equity
27.94%
Return on Assets
16.41%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
1.21
Quick Ratio
0.81

Sales & Book Value

Annual Sales
$45.31 billion
Price / Sales
2.98
Cash Flow
$5.75 per share
Price / Cash Flow
9.31
Book Value
$31.50 per share
Price / Book
1.70

Miscellaneous

Outstanding Shares
2,524,780,000
Free Float
2,499,528,000
Market Cap
$135.15 billion
Optionable
Optionable
Beta
0.56

Social Links

10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Paul HudsonMr. Paul Hudson (Age 56)
    CEO & Director
    Comp: $4.14M
  • Mr. Jean-Baptiste Chasseloup de ChatillonMr. Jean-Baptiste Chasseloup de Chatillon (Age 58)
    Exec. VP & CFO
  • Mr. Laurent Gilhodes
    Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard
    Chief Information officer
  • Dr. Josephine Fubara
    Chief Science Officer of Consumer Health Care
  • Eva Schaefer-Jansen
    Head of Investor Relations
  • Mr. Dante Beccaria
    Global Compliance Officer & VP
  • Mr. Roy Papatheodorou (Age 45)
    Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity
  • Mr. Josep Catlla
    Head of Communications
  • Mr. Pierre Chancel (Age 66)
    Sr. VP of Global Diabetes and Sr. VP of Global Marketing

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SNY Stock - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNY shares.
View SNY analyst ratings or view top-rated stocks.

What is Sanofi's stock price forecast for 2023?

8 brokers have issued 1-year target prices for Sanofi's stock. Their SNY share price forecasts range from $60.00 to $93.00. On average, they expect the company's share price to reach $82.40 in the next twelve months. This suggests a possible upside of 53.9% from the stock's current price.
View analysts price targets for SNY or view top-rated stocks among Wall Street analysts.

How have SNY shares performed in 2023?

Sanofi's stock was trading at $48.43 on January 1st, 2023. Since then, SNY stock has increased by 10.5% and is now trading at $53.53.
View the best growth stocks for 2023 here.

When is Sanofi's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our SNY earnings forecast.

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) announced its quarterly earnings data on Friday, July, 28th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.07. The business earned $10.85 billion during the quarter, compared to the consensus estimate of $11.47 billion. Sanofi had a net margin of 16.07% and a trailing twelve-month return on equity of 27.94%.

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Tuesday, May 30th. Stockholders of record on Wednesday, May 31st will be paid a dividend of $1.377 per share on Friday, June 23rd. This represents a dividend yield of 2.94%. The ex-dividend date is Tuesday, May 30th.
Read our dividend analysis for SNY.

What ETFs hold Sanofi's stock?

ETFs with the largest weight of Sanofi (NASDAQ:SNY) stock in their portfolio include Simplify Health Care ETF (PINK), VanEck Pharmaceutical ETF (PPH), Pacer BioThreat Strategy ETF (VIRS), Subversive Mental Health ETF (SANE), Horizon Kinetics Medical ETF (MEDX), Putnam Focused Large Cap Value ETF (PVAL), Invesco International Dividend Achievers ETF (PID) and Amplify International Enhanced Dividend Income ETF (IDVO).

Is Sanofi a good dividend stock?

Sanofi (NASDAQ:SNY) pays an annual dividend of $1.38 per share and currently has a dividend yield of 2.57%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 47.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 28.57% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.

What is Paul Hudson's approval rating as Sanofi's CEO?

277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).

What is Sanofi's stock symbol?

Sanofi trades on the NASDAQ under the ticker symbol "SNY."

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boston Partners (0.52%), Fisher Asset Management LLC (0.51%), BlackRock Inc. (0.38%), Bank of New York Mellon Corp (0.30%), Hotchkis & Wiley Capital Management LLC (0.09%) and Envestnet Asset Management Inc. (0.09%).
View institutional ownership trends.

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $53.53.

How much money does Sanofi make?

Sanofi (NASDAQ:SNY) has a market capitalization of $135.15 billion and generates $45.31 billion in revenue each year. The company earns $8.82 billion in net income (profit) each year or $2.92 on an earnings per share basis.

How many employees does Sanofi have?

The company employs 91,573 workers across the globe.

Does Sanofi have any subsidiaries?
The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More
How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The official website for the company is www.sanofi.com. The company can be reached via phone at (315) 377-4000, via email at ir@sanofi.com, or via fax at 33-1-53-77-43-03.

This page (NASDAQ:SNY) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -